110 related articles for article (PubMed ID: 17196106)
1. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis.
Stockley RA; Whitehead PJ; Williams MK
Respir Res; 2006 Dec; 7(1):147. PubMed ID: 17196106
[TBL] [Abstract][Full Text] [Related]
2. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
4. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
Kornmann O; Dahl R; Centanni S; Dogra A; Owen R; Lassen C; Kramer B;
Eur Respir J; 2011 Feb; 37(2):273-9. PubMed ID: 20693243
[TBL] [Abstract][Full Text] [Related]
5. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease.
Chapman KR; Arvidsson P; Chuchalin AG; Dhillon DP; Faurschou P; Goldstein RS; Kuipers AF;
Can Respir J; 2002; 9(3):178-85. PubMed ID: 12068339
[TBL] [Abstract][Full Text] [Related]
6. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Yates JC; Vestbo J;
N Engl J Med; 2007 Feb; 356(8):775-89. PubMed ID: 17314337
[TBL] [Abstract][Full Text] [Related]
7. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
Kardos P; Wencker M; Glaab T; Vogelmeier C
Am J Respir Crit Care Med; 2007 Jan; 175(2):144-9. PubMed ID: 17053207
[TBL] [Abstract][Full Text] [Related]
8. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease.
Ryan S; Doherty LS; Rock C; Nolan GM; McNicholas WT
Respiration; 2010; 79(6):475-81. PubMed ID: 19684384
[TBL] [Abstract][Full Text] [Related]
9. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
10. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
Hanania NA; Crater GD; Morris AN; Emmett AH; O'Dell DM; Niewoehner DE
Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533
[TBL] [Abstract][Full Text] [Related]
11. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary diseases.
Gupta RK; Chhabra SK
Indian J Chest Dis Allied Sci; 2002; 44(3):165-72. PubMed ID: 12206475
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD).
Boyd G; Morice AH; Pounsford JC; Siebert M; Peslis N; Crawford C
Eur Respir J; 1997 Apr; 10(4):815-21. PubMed ID: 9150318
[TBL] [Abstract][Full Text] [Related]
14. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
[TBL] [Abstract][Full Text] [Related]
15. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses.
Matera MG; Sanduzzi A; Ponticiello A; Vatrella A; Salzillo A; Cazzola M
Respiration; 2005; 72(5):466-70. PubMed ID: 16210884
[TBL] [Abstract][Full Text] [Related]
16. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.
Bourbeau J; Christodoulopoulos P; Maltais F; Yamauchi Y; Olivenstein R; Hamid Q
Thorax; 2007 Nov; 62(11):938-43. PubMed ID: 17557771
[TBL] [Abstract][Full Text] [Related]
17. [Inhaled corticosteroids in patients with COPD: maintain current guidelines].
Heijdra YF
Ned Tijdschr Geneeskd; 2007 Oct; 151(40):2195-7. PubMed ID: 17969568
[TBL] [Abstract][Full Text] [Related]
18. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
[TBL] [Abstract][Full Text] [Related]
19. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
[TBL] [Abstract][Full Text] [Related]
20. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
